; and (6) to develop and implement an ongoing mechanism to share feedback and information and develop strategies with the neurodegenerative disease community, including patients, treating physicians, national organizations that facilitate provision of care services, access, and research, researchers, drug sponsors, drug manufacturers, and Federal agencies. 4. Neurodegenerative disease action plan (a) In general Not later than 6 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall publish an action plan describing actions the Department of Health and Human Services, through the National Institutes of Health and Food and Drug Administration, intend to take during the 5-year period following publication of the plan with respect to program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives to— (1) foster the development of safe and effective drugs that improve the lives of people living with rare neurodegenerative diseases as quickly as possible; and (2) facilitate access to investigational drugs. (b) Contents The action plan published under subsection (a) shall— (1) identify appropriate representation from within the Food and Drug Administration and National Institutes of Health to be responsible for implementation of such action plan; and (2) include elements to facilitate— (A) interactions and collaboration between the Food and Drug Administration, including the review centers thereof, and stakeholders including patients, sponsors, and external biomedical community; (B) consideration of cross-cutting clinical and regulatory policy issues, including consistency of regulatory advice and decisionmaking; (C) identification of key regulatory science and policy issues critical to advancing development of safe and effective drugs